ETON Eton Pharmaceuticals

Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock

Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock
EN
13/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eton Pharmaceuticals

 PRESS RELEASE

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application ...

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company’s New Drug Application (NDA) for ET-600, a proprietary patented formulation of desmopressin oral solution, has been accepte...

 PRESS RELEASE

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3...

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market closes on June 27, as part of the 2025 Russell Indexes reconstitution. “Eton’s addition to the Russell 2000 and Russell 3000 Indexes is a sign...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 14, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydroc...

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution • KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million DEER PARK, Ill., May 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Foo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch